Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Wednesday, October 18, 2017 Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Wednesday, October 11, 2017 Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Upcoming and Recent Events > MORE
Date Title  
Thursday, September 28, 2017
9:00 AM ET
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Supporting Materials
PDF View Presentation 766.8 KB   Add to Briefcase
Tuesday, August 8, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2017 Q2 Quarterly Earnings Call
Supporting Materials
PDF View Presentation 957.7 KB   Add to Briefcase
Wednesday, June 7, 2017
11:00 AM ET
Jefferies 2017 Global Healthcare Conference
Supporting Materials
PDF View Presentation  1.9 MB   Add to Briefcase

FPRX (Common Stock)

Change (%)

Data as of 3:59 PM ET on Wednesday, October 18, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.